

July 2021

Dear Optum360 2021 *HCPCS Level II Expert* Customer:

The Centers for Medicare and Medicaid Services (CMS) has issued the following updates that can be marked in your book. Our customer service team is available to answer any questions at 1.800.464.3649, option 1.

Thank you for your patience and support of our ongoing efforts to deliver high-quality products. We value you as an Optum360 customer.

Sincerely,

Optum360
www.optum360coding.com

The following code changes are effective April 17, 2021:

Deleted Codes

M0239 Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring

Q0239 Injection, bamlanivimab-xxxx, 700 mg

The following code changes are effective May 6, 2021:

New Codes

M0244 Intravenous infusion, casirivimab and imdevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency

M0246 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency

The following code changes are effective June 6, 2021:

New Codes

Q0244 Injection, casirivimab and imdevimab, 1200 mg

Revised Codes

M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring

M0244 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency

The following code changes are effective July 1, 2021:

New Codes

- A9593 Gallium Ga-68 PSMA-11, diagnostic, (UCSF), 1 mCi
- A9594 Gallium Ga-68 PSMA-11, diagnostic, (UCLA), 1 mCi
- C1761 Catheter, transluminal intravascular lithotripsy, coronary
- C9075 Injection, casimersen, 10 mg
- C9076 Lisocabtagene maraleucel, up to 110 million autologous anti-CD19 CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- C9077 Injection, cabotegravir and rilpivirine, 2 mg/3 mg
- C9078 Injection, trilaciclib, 1 mg
- C9079 Injection, evinacumab-dgnb, 5 mg
- C9080 Injection, melphalan flufenamide HCl, 1 mg
- C9778 Colpopexy, vaginal; minimally invasive extraperitoneal approach (sacrospinous)
- G0327 Colorectal cancer screening; blood-based biomarker
- J0224 Injection, lumasiran, 0.5 mg
- J1951 Injection, leuprolide acetate for depot suspension (Fensolvi), 0.25 mg
- J7168 Prothrombin complex concentrate (human), Kcentra, per IU of Factor IX activity
- J9314 Injection, romidepsin, nonlyophilized (e.g., liquid), 0.1 mg
- J9348 Injection, naxitamab-gqgk, 1 mg
- J9353 Injection, margetuximab-cmkb, 5 mg
- Q5123 Injection, rituximab-arrx, biosimilar, (Riabni), 10 mg

Deleted Codes

- C9065 Injection, romidepsin, nonlyophilized (e.g. liquid), 1 mg
- C9074 Injection, lumasiran, 0.5 mg
- C9132 Prothrombin complex concentrate (human), Kcentra, per IU of Factor IX activity